Color Health vs Pfizer

Side-by-side comparison of AI visibility scores, market position, and capabilities

Pfizer leads in AI visibility (93 vs 54)
Color Health logo

Color Health

ChallengerHealthcare

Population Health & Genomic Screening

Color Health is a population health company offering employer- and health-system-sponsored genomic screening, cancer risk assessment, and proactive care navigation; partnered with the American Cancer Society;

AI VisibilityBeta
Overall Score
C54
Category Rank
#197 of 596
AI Consensus
80%
Trend
stable
Per Platform
ChatGPT
56
Perplexity
51
Gemini
51

About

Color Health (operating as Color) is a San Francisco-based health technology company founded in 2013 by Othman Laraki and Elad Gil, focused on making population-scale genomic and preventive care programs accessible to employers, health plans, and public health agencies. Its core platform combines clinical-grade genetic testing — including hereditary cancer and cardiovascular risk panels — with care navigation, genetic counseling, and longitudinal patient management, enabling organizations to stand up comprehensive genomic health programs at scale. Color has partnered with the American Cancer Society to expand cancer screening and early-detection access to underserved populations, and has run large public health genomic programs in partnership with federal and state agencies.

Full profile
Pfizer logo

Pfizer

LeaderHealthcare Tech

Enterprise

Global biopharma with $63.6B FY2024 revenue; $43B Seagen ADC acquisition rebuilds post-COVID pipeline; patent cliff 2026-2028 for Eliquis; activist Starboard Value pushing restructuring.

AI VisibilityBeta
Overall Score
A93
Category Rank
#1 of 596
AI Consensus
80%
Trend
stable
Per Platform
ChatGPT
94
Perplexity
89
Gemini
94

About

Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The company trades on NYSE (PFE) and reported $63.6 billion in total revenues for FY2024, normalizing from pandemic highs of $100 billion-plus in 2021-2022 driven by Comirnaty COVID-19 vaccine revenues with BioNTech and Paxlovid COVID antiviral sales. CEO Albert Bourla has led a strategic pivot to reset the company's long-term growth profile, anchored by the landmark $43 billion acquisition of Seagen in December 2023, adding a world-class antibody-drug conjugate (ADC) oncology pipeline including Padcev, Tukysa, Adcetris, and Tivdak.

Full profile

AI Visibility Head-to-Head

54
Overall Score
93
#197
Category Rank
#1
80
AI Consensus
80
stable
Trend
stable
56
ChatGPT
94
51
Perplexity
89
51
Gemini
94
50
Claude
92
57
Grok
98

Key Details

Category
Population Health & Genomic Screening
Enterprise
Tier
Challenger
Leader
Entity Type
brand
company

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.